FOR
IMMEDIATE RELEASE
Indivior to Host Analyst
Teach-in Event in New York City; Reconfirms Full Year 2024
Guidance
Richmond, VA, May 23, 2024 - Indivior
PLC (LSE: INDV; Nasdaq: INDV), a leading
addiction treatment company, announced that in anticipation of the expected primary listing of the Company's
shares on Nasdaq, members of Indivior's senior leadership team will
be hosting an analyst teach-in event today in New York City. The
event, which will be webcast (see details below), is intended to
provide an in-depth overview of Indivior's growth and value
creation path. During the event, the Company will reconfirm its
unchanged FY 2024 guidance as set forth below.
|
FY
2024
|
Net
Revenue (NR)1
|
$1,240m to $1,330m
(+18% at midpoint vs. FY
2023)
|
SUBLOCADE NR
|
$820m to $880m
(+35% at midpoint vs. FY
2023)
|
OPVEE® NR
|
$15m to $25m1
|
PERSERIS NR
|
$55m to $65m
(+43% at midpoint vs. FY
2023)
|
SUBOXONE Film Market Share
|
Assumes historic rate of share
decline in FY 2024 of 1 to 2 percentage points and the potential
impact from a fourth buprenorphine/naloxone sublingual film generic
in the U.S. market
|
Adjusted Gross Margin
|
Low to mid-80s range
|
Adjusted SG&A
|
($575m) to ($590m)
|
R&D
|
($120m) to ($130m)
|
Adjusted Operating Profit
|
$330m to $380m
|
1 The OPVEE NR guidance for FY 2024
includes approximately $8m as part of a multi-year agreement with
the U.S. Biomedical Advancement Research and Development Authority
(BARDA).
Link to today's analyst teach-in
event
Webinar Registration - Zoom
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,100 individuals globally and its portfolio of
products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting https://www.linkedin.com/company/indivior.
Important Cautionary Note
Regarding Forward-Looking Statements
This announcement contains certain statements that are forward-looking.
Forward-looking statements include, among other things, statements
regarding: the Indivior Group's financial guidance including
operating and profit margins for 2024 and its medium- and long-term
growth outlook; assumptions regarding expected changes in share and
expectations regarding the extent and impact of competition;
assumptions regarding future exchange rates; strategic priorities,
strategies for value creation, and operational goals; expected
future growth and expectations for sales levels for particular
products, and expectations regarding the future impact of factors
that have affected sales in the past; expected growth rates,
growing normalization of medically assisted treatment for opioid
use disorder, and expanded access to treatment; our product
development pipeline and potential future products, expectations
regarding regulatory approval of such product candidates, the
timing of such approvals, and the timing of commercial launch of
such products or product candidates, and eventual annual revenues
of such future products; expectations regarding future production
at the Group's Raleigh, North Carolina manufacturing facility; our
intention to seek shareholder approval in May 2024 to facilitate a
primary listing in the U.S. while maintaining a secondary listing
in the U.K., and the expected timing and potential benefits of such
listing; and other statements containing the words "believe,"
"anticipate," "plan," "expect," "intend," "estimate," "forecast,"
"strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and variations
thereon and similar expressions. By their nature, forward-looking
statements involve risks and uncertainties as they relate to events
or circumstances that may or may not occur in the
future.
Actual results may differ materially
from those expressed or implied in such statements because they
relate to future events. Various factors may cause differences
between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent
Indivior PLC Annual Report and in subsequent releases; the
substantial litigation and ongoing investigations to which we are
or may become a party; our reliance on third parties to manufacture
commercial supplies of most of our products, conduct our clinical
trials and at times to collaborate on products in our pipeline; our
ability to comply with legal and regulatory settlements, healthcare
laws and regulations, requirements imposed by regulatory agencies
and payment and reporting obligations under government pricing
programs; risks related to the manufacture and distribution of our
products, most of which contain controlled substances; market
acceptance of our products as well as our ability to commercialize
our products and compete with other market participants;
competition; the uncertainties related to the development of new
products, including through acquisitions, and the related
regulatory approval process; our dependence on third-party payors
for the reimbursement of our products and the increasing focus on
pricing and competition in our industry; unintended side effects
caused by the clinical study or commercial use of our products; our
ability to successfully execute acquisitions, partnerships, joint
ventures, dispositions or other strategic acquisitions; our ability
to protect our intellectual property rights and the substantial
cost of litigation or other proceedings related to intellectual
property rights; the risks related to product liability claims or
product recalls; the significant amount of laws and regulations
that we are subject to, including due to the international nature
of our business; macroeconomic trends and other global developments
such as armed conflicts and pandemics; the terms of our debt
instruments, changes in our credit ratings and our ability to
service our indebtedness and other obligations as they come due;
changes in applicable tax rate or tax rules, regulations or
interpretations and our ability to realize our deferred tax assets;
and volatility in our share price due to factors unrelated to our
operating performance or that may result from the potential move of
our primary listing to the U.S.
Forward-looking statements speak
only as of the date that they are made and should be regarded
solely as our current plans, estimates and beliefs. Except as
required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking
statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events.
Media
Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-